Ad blocking detected

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Canntab Therapeutics Limited (C:PILL)

Business Focus: Alternative Medicine

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEDAR
Company Contact
Address: 1 Adelaide St E Suite 801
Tel: N/A
IR: See website
Key People
Larry Latowsky
Executive Chairman of the Board, Chief Executive Officer
Jeff Renwick
President, Head of Manufacturing, Director
Richard Goldstein
Chief Financial Officer, Director
Joshi Laxminarayan
Chief Scientific Officer
Barry Polisuk
Secretary, Director
Business Overview
Canntab Therapeutics Ltd, formerly Telferscot Resources Inc, is a Canada-based company engaged in alternatywe medicine sector. The Company is dedicated to the research and development of oral dosage therapeutic formulations of cannabis and a range of oral dosage products that treat different ailments by delivering a uniform dosage of medicinal cannabis extract. The Company developed bi-layered tablets that offer an immediate dosage and therefore immediate release of active ingredients, combined with its patent pending extended release formulations. Its Gel Capsules offer doctors and patients a uniform amount of THC/CBD oil extract, in a quick dissolving gel capsule. The Companys flash melt tablets are designed to dissolve immediately when placed under the tongue. They deliver an dosage to the patient, offering instant relief.
Financial Overview
For the nine months ended 28 February 2021, CanntabTherapeutics Ltd revenues increased from C$133K to C$843K.Net loss increased 22% to C$2.1M. Revenues reflect anincrease in demand for the Company's products and servicesdue to favorable market conditions. Higher net lossreflects Share based compensation Depreciation of increasefrom C$120K to C$518K (expense), Depreciation increase of98% to C$297K (expense).
Reporting Currency: Canadian Dollars
Enterprise value: $27.00M as of Feb 28, 2021
Annual revenue (TTM): $0.84M as of Feb 28, 2021
EBITDA (TTM): -$2.48M as of Feb 28, 2021
Net annual income (TTM): -$2.99M as of Feb 28, 2021
Free cash flow (TTM): -$3.28M as of Feb 28, 2021
Net Debt Last Fiscal Year: $0.59M as of Feb 28, 2021
Shares outstanding: 35,551,437 as of Feb 28, 2021
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization